Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

tion has occurred. Consolidation or financial difficulties could cause customers to reduce their inventory levels, or otherwise reduce purchases of the Group's products. Such actions could have an adverse effect on the Group's revenues, financial condition and results of operations. A significant portion of the Group's Specialty Pharmaceuticals product sales are made to major pharmaceutical wholesale distributors as well as to large pharmacies in both the US and Europe. Consequently, product sales and growth comparisons may be affected by fluctuations in the buying patterns of major distributors and other trade buyers. These fluctuations may result from seasonality, pricing, wholesaler buying decisions, or other factors. In addition, a significant portion of the Group's revenues for certain products for treatment of rare genetic diseases are concentrated with a small number of customers. Changes in the buying patterns of those customers may have an adverse effect on the Group's financial condition and results of operations.

The outsourcing of services can create a significant dependency on third parties, the failure of whom can affect the ability to operate the Group's business and to develop and market products

The Group has entered into many agreements with third parties for the provision of services to enable it to operate its business. If the third party can no longer provide the service on the agreed basis, the Group may not be able to continue the development or commercialization of its products as planned or on a commercial basis. Additionally, it may not be able to establish or maintain good relationships with the suppliers.

The Group has also entered into licensing and co-development agreements with a number of parties. There is a risk that, upon expiration or termination of a third party agreement, the Group may not be able to renew or extend the agreement with the third party as commercial
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
(Date:6/1/2015)... 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: FRX, ... results from a poster presented today entitled, "Anti-tumor ... phase III trial of the efficacy of sodium ... cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." ... of Clinical Oncology (ASCO) 2015 Annual Meeting in ...
(Date:6/1/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today that ... leading commercial food testing laboratory based in southwest ... as a base for the company,s new operations in ... House was incorporated in 1990, and its business has ... water quality testing for major hotels and restaurants in its ...
(Date:6/1/2015)... Frederick MD (PRWEB) June 01, 2015 ... that they have entered into a commercial collaboration ... both companies will combine their technologies and work ... cell (MSC) regenerative technology. RoosterBio and Sistemic will ... and technologies to build more precise and relevant ...
Breaking Biology Technology:Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Neogen acquires India food safety company 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... been granted its 33rd U.S. Patent, # 7,608,257, ... With a Virus." The patent claims cover methods ... chemotherapeutic agents to treat patients that are refractory ...
... , COLUMBIA, Md., Oct. 27 Precision ... a component of the National Cancer Institute (NCI),s Clinical ... improving the number and standardizing the quality of monoclonal ... contract award is the result of a third solicitation ...
... Oct. 27 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,it has received its third purchase order ... and Information Technology for the national,stockpiling plan. Under this ... million doses of PANFLU.1 (15ug/0.5ml) for the Chinese central,government. ...
Cached Biology Technology:Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
(Date:6/1/2015)... , June 1, 2015 ... "Next Generation Biometrics Market by Application (Government, Military ... Travel & Immigration, and Security), Technology (Face Recognition, ... Signature Recognition, Vein Recognition, and Others), Function (Contact ... , Europe , APAC, ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... topping-out ceremony for the experimental hall of PETRA III ... On occasion of the structural completion of the building, German ... von Beust visited the Helmholtz research centre DESY. Its new ... 2009. PETRA III is a milestone on the way ...
... by Indiana University researchers found the chlorinated flame retardant ... northeastern United States, with by far the highest concentrations ... chemical is produced. The study, by Xinghua Qui ... Public and Environmental Affairs, was published online last week ...
... expected this century. It is likely to intensify droughts, ... migrations and potential conflicts in the areas migrated to. ... Hurricane Katrina in the US, Rafael Reuveny from Indiana ... environmental degradation on population migration, or ecomigration. He examines ...
Cached Biology News:Brilliant perspectives 2Brilliant perspectives 3The proof is in the tree bark 2Environmental exodus 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
... a member of the caudal-related homeobox family, ... both proliferation and differentiation in intestinal epithelial ... triggering cells towards the phenotype of differentiated ... maintenance of the phenotype. Clone CDX2-88 reacts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: